[ET Net News Agency, 17 January 2018] UOB Kay Hian lifted its target price for IMAX
China (01970) to HK$26 from HK$25, and maintained its "buy" rating.
The research house said China's box office growth beat its estimate with growth of 15%
yoy in 2017. Despite being a laggard initially in 1H 2017, IMAX China's box office growth
accelerated to a high single digit in 2H 2017 on the back of a sector recovery and its new
screening strategy.
UOBKH expects IMAX China's recovery trend to sustain into 2018. The research house
fine-tuned its 2017-19 net profit forecasts by -1%, +1% and +2% respectively factoring in
lower IMAX box office but the sales boost from additional sales screen installations. Its
2017-19 earnings estimates represent a 13% CAGR. (KL)